AMLo Biosciences
Jane Meaney has over 30 years of commercial experience gained in blue chip and start-up pharmaceutical and medical technology companies. She has very wide-ranging marketing experience in healthcare across the NHS and private sectors in UK and Europe. Most recently Jane worked as Marketing Director for an Oxford University spin-out company. She brought a CE-marked cancer biomarker to market and developed a novel digital pathology cancer prognostic device with the team; transforming the company from an academic spin-out to a fully functioning commercial entity. This experience will help AMLo become a successful commercial business. Jane is a biology graduate and an MBA.
This person is not in any offices
AMLo Biosciences
Formed in late 2017, AMLo Biosciences is dedicated to providing a prognostic test for early AJCC Stage I and Stage II melanoma to better identify patients’ true risk of disease progression.